Related Experiment Videos
Protein kinase C isozymes in stroke
Wen-Hai Chou1, Robert O Messing
1Ernest Gallo Clinic and Research Center, University of California San Francisco, Emeryville, California 94608, USA.
Trends in Cardiovascular Medicine
|May 12, 2005
Summary
Protein kinase C (PKC)delta plays a key role in stroke-related reperfusion injury. Inhibiting PKCdelta may reduce this injury and improve outcomes after thrombolytic therapy for stroke.
Area of Science:
- Neuroscience
- Biochemistry
- Cardiovascular Research
Background:
- Stroke is a major cause of death and disability globally.
- Thrombolytic agents are used to treat thromboembolic stroke but can cause hemorrhage and reperfusion injury.
- Protein kinase C (PKC) signaling pathways are implicated in both stroke protection and injury.
Purpose of the Study:
- To investigate the role of specific PKC isoforms in ischemic stroke and reperfusion injury.
- To evaluate the potential of targeting PKCdelta for therapeutic benefit in stroke.
Main Methods:
- Utilized experimental stroke models.
- Employed mouse genetics to study PKC isoform function.
- Tested selective peptide inhibitors and activators of PKC.
Main Results:
- PKCepsilon is involved in ischemic preconditioning.
- PKCdelta and PKCgamma are implicated in tissue injury following stroke.
- PKCdelta, present in neutrophils and brain tissue, is crucial for reperfusion injury.
- PKCdelta-specific inhibitors showed potential in reducing reperfusion injury.
Conclusions:
- PKCdelta is a critical mediator of reperfusion injury after stroke.
- Targeting PKCdelta with specific inhibitors may represent a novel therapeutic strategy to improve outcomes in stroke patients undergoing thrombolysis.